Performance of 68 Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence

Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC ( Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary di...

Full description

Saved in:
Bibliographic Details
Published in:Current urology reports 2017-09, Vol.18 (11), p.84
Main Authors: Bailey, Jason, Piert, Morand
Format: Article
Language:English
Subjects:
Edetic Acid - analogs & derivatives
Humans
Male
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Recurrence, Local - pathology
Neoplasm Staging - methods
Positron Emission Tomography Computed Tomography - methods
Positron-Emission Tomography - methods
Prostate-Specific Antigen - blood
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Radiopharmaceuticals
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC ( Ga-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. Ga-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, Ga-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that Ga-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (
ISSN:1534-6285